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Introduction: Ablation in the left ventricle (LV) is associated with a risk of thromboembolism.
There are limited data on the use of specific thromboembolic prophylaxis strategies postablation.
We aimed to evaluate a thromboembolic prophylaxis protocol after ventricular tachycardia (VT)
ablation.
Methods and results: The index procedures of 217 patients undergoing ablation for infarct-
related VT with open irrigated-tip catheters were included. Patients with large LV endocar-
dial ablation area (>3 cm between ablation lesions) were started on low-dose, slowly escalating
unfractionated heparin (UFH) infusion 8 hours after access hemostasis, followed by 3 months of
anticoagulation. Patients with less extensive ablation were treated only with antiplatelet agents
postablation. Postablation bridging anticoagulation was used in 181 (83%) patients. Of them, 11
(6%) patients experienced bleeding events (1 required endovascular intervention) and 1 (0.6%)
experienced lower extremity arterial embolism requiring vascular surgery. Systemic anticoagu-
lation was prescribed in 190 (89%) of 214 patients discharged from the hospital (warfarin in
98%), while the rest received single- or dual-antiplatelet therapy alone. Patients treated with
an anticoagulant had significantly longer radiofrequency time compared to patients treated with
antiplatelet agents only. One (0.5%) of the patients treated with oral anticoagulation experienced
major bleeding 2 weeks postablation. No thromboembolic events were documented in either the
anticoagulation or the “antiplatelet only” group postdischarge.
Conclusion:A slowly escalating bridging regimen of UFH, followed by 3months of oral anticoagu-
lation, is associatedwith low thromboembolic and bleeding risks after infarct-related VT ablation.
In the absence of extensive ablation, antiplatelet therapy alone is reasonable.
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1 INTRODUCTION
Catheter ablation of the left-sided cardiac chambers is associated
with a risk of thromboembolism, and most of the current knowl-
edge on the incidence, risk factors, and prophylaxis strategies is
derived from atrial fibrillation (AF) ablation procedures.1,2 In left ven-
tricular (LV) ablations, particularly for ventricular tachycardia (VT),
the prolonged radiofrequency (RF) energy application over extensive
endocardial areas contributes to an increased thromboembolic risk,
which is mitigated by the use of high anticoagulant doses intrapro-
cedurally; however, the thromboembolic risk may persist beyond the
intraprocedural period. While clinically overt periprocedural cere-
brovascular events are uncommon, silent embolic events are frequent
(more than 50% of patients) as shown by a recent study in which
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patients underwent brain magnetic resonance imaging (MRI) after LV
RF ablation for ventricular arrhythmias.3
There are very limited data regarding the effectiveness and safety
of postablation anticoagulation strategies, including bridging and post-
discharge anticoagulation. In the multicenter Thermocool VT study, a
3-month course of warfarin was used postprocedurally if ablation had
been performed over an area with >3 cm distance between ablation
sites, otherwise full-dose aspirin was used.4 The benefits of anticoagu-
lation, however, need to beweighed against the risks of bleeding in the
immediate postprocedural period and during follow-up. The current
study aimed at assessing the feasibility, safety, and effectiveness of a
thromboembolic prophylaxis protocol in patients undergoing catheter
ablation for infarct-related VT.
2 METHODS
2.1 Patient population and preprocedural testing
We included consecutive patients undergoing ablation for infarct-
related VT with open irrigated-tip catheters between 2008 and
2015. Patients either had a clinical history of myocardial infarction
or evidence of prior infarction on cardiac imaging. All patients had
a transthoracic echocardiogram with or without echocardiographic
contrast on the day before the procedure for assessment of LV throm-
bus. A preprocedural transesophageal echocardiogram (TEE) was
performed in patients presenting with AF for assessment of left atrial
(LA) thrombus and in patients with a history of unexplained stroke
for assessment of atheromatous disease in the thoracic aorta. The
presence of LA thrombus or mobile, pedunculated LV thrombus was
considered a contraindication for the procedure, while chronic lami-
nated LV thrombus was not a contraindication.5 In case of a laminated
LV thrombus, the procedure was performed if deemed to be urgent
and benefits outweighed the risk. The thrombus was identified with
intracardiac echocardiography and marked on the electroanatomic
map so that catheter manipulation could be avoided in that area. In
nonurgent cases, the procedure was performed after 6–8 weeks of
therapeutic anticoagulation. The first ablation performed at our insti-
tution was considered the index procedure. This retrospective study
was approved by the institutional review board of the University of
Michigan.
2.2 Electrophysiology procedure
After informed consent, arterial and venous femoral access was
obtained and multielectrode catheters were positioned in the high
right atrium, the His position, and the right ventricular apex. Elec-
troanatomical mapping was performed with open-irrigation abla-
tion catheters (CARTO and Thermocool, Biosense Webster, Inc., Dia-
mond Bar, CA, USA). Multipolar mapping or contact force-sensing
catheters were not used in any of the patients, whereas intracar-
diac echocardiography was used in all patients. Electrograms were fil-
tered at 50–500 Hz and stored on an optical disc (St. Jude Medical,
St. Paul, MN, USA). In patients who did not present spontaneously
in VT, programmed ventricular stimulation was performed with up to
four extrastimuli from multiple right ventricular locations with cou-
pling intervals down to 200 milliseconds or refractoriness, whichever
occurred first. Entrainment mapping was performed for hemodynam-
ically tolerated VT with ablation at sites of concealed entrainment.
Ablation during sinus rhythm at sites with matching pace maps or
fragmented electrograms or low-voltage electrograms was performed
in hemodynamically unstable VT. Cardioversion was performed as
needed for patients with hemodynamically unstable VTs that were not
promptly pace terminable. At the conclusion of the procedure, pro-
grammed ventricular stimulation was repeated from two ventricular
sites with up to four extrastimuli. Procedural success was classified as
complete when no sustained monomorphic VT was inducible, partial
when only nonclinical VTs were inducible, and failed when clinical VTs
were inducible at the end of the procedure.
2.3 Anticoagulation protocol
Before the procedure, in patients taking warfarin the medication was
discontinued 3–4 days in advance and the international normalized
ratio (INR) was allowed to decrease below 1.5 in anticipation of the
need for arterial access. Patients with an indication for preprocedu-
ral bridging (AF with recent stroke, recent venous thromboembolism,
mechanical mitral, or older generation mechanical aortic valve) were
admitted before the procedure for bridging with intravenous unfrac-
tionated heparin (UFH). Direct oral anticoagulants (DOACs) were
stopped 1–2 days before the procedure.
After vascular access, 3,000 units of UFH were administered at
the beginning of the procedure. If mapping in the LV was necessary,
the patient received additional heparin according to a weight-based
nomogram to achieve an activated clotting time (ACT) of 250–300 sec-
onds. In cases requiring subxiphoid percutaneous epicardial access
for mapping/ablation, anticoagulation was interrupted to allow for
epicardial puncture with an ACT < 140 seconds and it was restarted if
additional endocardial mapping/ablation was required. At the conclu-
sion of the procedure, the arterial and venous sheaths were removed
manually when the ACT was <150 seconds. The use of protamine for
anticoagulation reversal before sheath removal was at the discretion
of the operator.
The protocol of postablation anticoagulation is outlined in Figure 1.
In summary, patients with a large ablation area (>3 cm between abla-
tion sites4) or with other indications for bridging anticoagulation were
treated with a low-dose, slowly escalating bridging regimen of UFH
while transitioned to oral anticoagulation. Warfarin (target INR 2–
3) was the preferred oral anticoagulant for an intended course of
3 months. Low molecular weight heparin (LMWH) was avoided for
48 hours after sheath removal. In the absence of bleeding while on
UFH, half-dose LMWHcould be used afterUFHdiscontinuation on the
day of discharge until the INR was within target range in patients who
were prescribed warfarin. If a patient was on a DOAC prior to the pro-
cedure, thismedicationwas restarted as early as 48 hours after sheath
removal provided therewasnobleeding complication. In patientswith-
out extensive LV endocardial ablation, full-dose aspirin, or clopidogrel
plus aspirinwereusedat thephysician'sdiscretion insteadof therapeu-
tic anticoagulation.
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F IGURE 1 Postablation anticoagulation protocol. INR = international normalized ratio; LV = left ventricle; PTT = partial thromboplastin time
[Color figure can be viewed at wileyonlinelibrary.com]
2.4 Data collection and definition of clinical events
Baseline demographics, clinical, and procedural characteristics were
collected, including the use of protamine at the end of the procedure,
the use of bridging anticoagulation in the immediate postprocedural
period, and the use of posthospitalization anticoagulation.
Patients were seen in routine clinical follow-up 2–3 months after
the procedure, or sooner as indicated. Follow-up was obtained from
clinic or emergency room visits, hospital admissions, or by contact-
ing the referring physicians. The first thromboembolic incident (stroke,
transient ischemic attack [TIA], peripheral arterial embolism) and
bleeding events in the 3 months postablation were documented (in-
hospital and postdischarge). Bleeding events were classified as major
if blood transfusion or endovascular or other surgical interventionwas
required. We used a 3-month cutoff for event definition because the
duration of anticoagulation for the sole indication of VT ablation was
a maximum of 3 months. Also, any events beyond 3 months after the
procedure aremost likely unrelated to the procedure.
2.5 Data analysis
Categorical variables are reported as frequencies and percentages,
while continuous variables are reported as means ± standard devia-
tions, ormedians and interquartile ranges (IQRs) for normally and non-
normally distributed variables, respectively. Normality of distribution
was assessed by the Shapiro–Wilk test. Categorical baseline charac-
teristics and procedural variables were compared by the Fisher's exact
or chi-square testing, as appropriate, for the groups with versus with-
out postdischarge anticoagulation. Group comparisons for continuous
variables were performed with two-sided Student's t-test orWilcoxon
rank-sum test as appropriate. P values are two-tailed and P< 0.05was
considered statistically significant. Analyses were performed in Stata
14.2 (StataCorp, College Station, TX, USA).
3 RESULTS
3.1 Baseline characteristics
The baseline characteristics of the study population are shown in
Table 1. The index procedures of 217 patients were included. Sixty-
four (29%) patients had a prior VT ablation procedure at other insti-
tutions prior to the index procedure. Twenty-five patients (12%) had
a history of stroke or TIA, 91 (42%) had a history of AF, and 19 (9%)
had a history of LV thrombus. All patients were taking aspirin or other
agents (clopidogrel, ticagrelor, or dipyridamole) as single or combina-
tion antiplatelet therapy at baseline.
3.2 Procedural characteristics
All procedures requiring LV mapping and ablation were performed
via a retrograde aortic approach except for two procedures that
were performed transseptally due to the presence of ascending aor-
tic mural thrombus or large atheromatous plaques. Patients received
intraproceduralUFHexcept for2patientswith suspectedor confirmed
heparin-induced thrombocytopenia who received argatroban during
and after the procedure. All patients underwent endocardial mapping
andablation (LVn=174,RVn=3, LV+RVn=40),while 4patients also
underwent epicardial mapping/ablation via a percutaneous subxiphoid
approach.
The patients had a median of 1 (IQR 1–3) documented clinical
VT and a median of 7 (IQR 4–10) induced VTs. Median RF applica-
tion time was 82.5 (IQR 42–126) minutes with median total proce-
dure time of 452.5 (IQR 354–558) minutes. Postablation, 115 (53%)
patients had completely successful procedures (no inducible VT), while
96 (44%) patients had a partially successful or failed procedure. In 3
patients, the procedure was complicated by pericardial effusion, two
ofwhich required emergent pericardiocentesis. Both patients received
protamine for reversal of the heparin effect before the pericardiocen-
tesis. In both patients, the drain was removedwithin 48 hours. Neither
of the 2 patients received bridging heparin or warfarin postprocedure.
One patient was restarted on aspirin 81 mg daily (long-term medica-
tion) 3 days after the procedure and the other patient was restarted
on clopidogrel 75 mg daily (long-term medication) 2 weeks after the
procedure. Overall, protamine was administered in 18 (8%) cases for
anticoagulation reversal prior to sheath removal at the end of the pro-
cedure.
3.3 Early postprocedural anticoagulation and
clinical events
After initial access site hemostasis and before any anticoagulationwas
initiated, 17 (8%) patients had minor access site bleeding and three
(1%) had a major access site complication (retroperitoneal bleeding
requiring blood transfusion, n = 1; femoral artery pseudoaneurysm
requiring thrombin injection, n = 1; and access site bleeding requir-
ing vascular surgery, n= 1). Overall, bridging anticoagulation was used
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TABLE 1 Clinical and procedural characteristics in the overall population and in patientswith andwithout systemic anticoagulation at discharge




(n= 24)a P Value
Age (years) (mean± SD) 67.8 (9.1) 67.7 (8.9) 68.3 (10.9) 0.73
Male, n (%) 199 (92) 176 (93) 20 (83) 0.15
LVEF, median (IQR) 27 (20–40) 25 (20–35) 40 (28–55) <0.001
Hypertension, n (%) 167 (77) 146 (77) 18 (75) 0.88
Dyslipidemia, n (%) 178 (82) 157 (83) 18 (75) 0.36
Diabetes, n (%) 69 (32) 58 (31) 10 (42) 0.26
Atrial fibrillation, n (%) 91 (42) 80 (42) 9 (38) 0.68
Stroke or TIA, n (%) 25 (12) 22 (12) 3 (13) 0.89
Peripheral vascular disease, n (%) 33 (15) 33 (17) 0 (0) 0.03
Chronic renal failure, n (%) 42 (19) 38 (20) 3 (13) 0.39
Prior ablation, n (%) 64 (29) 58 (31) 6 (25) 0.59
ICD shock within prior 3months, n (%) 185 (85) 165 (87) 17 (71) 0.04
Prior VT storm, n (%) 66 (30) 60 (32) 6 (25) 0.52
Number of clinical VTs, median (IQR) 1 (1–3) 1 (1–3) 1 (1–1) 0.03
Number of induced VTs, median (IQR) 7 (4–10) 7 (5–11) 3 (1.5–6) <0.001
Procedure time (minutes), median (IQR) 452.5 (354–558) 460 (380–566) 337 (222–414) 0.001
RF time (minutes), median (IQR) 82.5 (42–126) 90.5 (52–140) 15 (7–35) <0.001
Complete or partial success, n (%) 204 (94) 183 (96) 18 (75) 0.01
Protamine use, n (%) 18 (8) 13 (7) 4 (17) 0.12
aAmong patients whowere discharged alive (3 patients died in hospital).
LVEF= left ventricular ejection fraction; SD= standard deviation; IQR= interquartile range; TIA= transient ischemic attack; ICD= implantable cardioverter
defibrillator; VT= ventricular tachycardia; RF= radiofrequency.
in 181 (83%) patients (UFH in 126 [70%], LMWH in 11 [6%], UFH
followed by LMWH in 42 [23%], and argatroban in 2 [1%]), while
the remaining 36 (17%) patients did not receive bridging due to lim-
ited endocardial LV ablation (n = 33) or major periprocedural access
site complication (n = 3). Among patients receiving bridging antico-
agulation, in-hospital bleeding occurred in 11 (6%) patients after a
mean of 1.8 days, including minor access site bleeding in 8 patients,
major access site bleeding and pseudoaneurysm in 1 patient (requir-
ing thrombin injection), andhematuria in 2patientswith indwelling uri-
nary catheters (both treated conservatively).
One patient (0.6% of those receiving bridging anticoagulation)
had a thromboembolic event in the early postablation period. This
patient had a lower extremity arterial embolism presenting with pain
and paresthesias 12 hours after the procedure and required surgical
embolectomy and fasciotomies for compartment syndrome with com-
plete clinical recovery. After the embolectomy, the patient remained
on UFH infusion for 5 days (target PTT 60–70 seconds) and was then
transitioned towarfarin long-term for secondary prevention of arterial
thrombosis, along with aspirin 81 mg and clopidogrel 75 mg daily. In
this patient, ablation was performed along the inferior and inferosep-
tal LV over a total area of 31 cm2. All RF applications were performed
in the LV endocardium with the exception of one RF application in the
RV apex. The patient received protamine for anticoagulation reversal
at the end of the procedure due to the presence of a small pericardial
effusion. It is unknown if this patient had aortic atheromas as hedid not
have an indication for preablation TEE and the transthoracic echocar-
diogramdidnot visualize the aorta adequately.Nodefinite intracardiac
source of embolismwas identified by transthoracic echocardiography.
3.4 Postdischarge anticoagulation and clinical
events
Three (1.4%) patients died during the index hospitalization due to sep-
tic shock (n = 1) or cardiogenic shock (n = 2) at a mean of 11 days
postablation. Among the 214 patients who were discharged, systemic
anticoagulation was prescribed in 190 (89%) patients. In 81 (43%)
patients, postablation thromboembolic prophylaxis was the sole indi-
cation for anticoagulation, whereas 109 (57%) patients had concomi-
tant indications for long-term anticoagulation, most commonly AF
(Table 2).
The anticoagulation regimen consisted of warfarin (INR target 2–3)
in most patients (n = 186, 98%) and 1 patient was treated with enoxa-
parin for 2 months due to a history of warfarin intolerance (Figure 2).
Among patients receiving warfarin, 53 patients were also prescribed
LMWH for bridging anticoagulation at discharge until the INR was
therapeutic. Three (1%) patients who were taking DOACs for AF prior
to the VT ablation were restarted on the DOAC (dabigatran n = 2,
rivaroxaban n = 1) upon discharge. Among patients on therapeutic
anticoagulation, 181 (95%) were also discharged on one (n = 148)
or two (n = 33) antiplatelet agents. Twenty-four (11%) patients with
less extensive LV ablation were treated only with antiplatelet agents,
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LV ablation (as the sole
indication)
81 (43)
Atrial fibrillation 90 (47)
LV thrombus 12 (6)
LV aneurysm 2 (1)
Mechanical valve 2 (1)
LV assist device 2 (1)
DVT/PE 5 (3)
LV= left ventricle; DVT= deep vein thrombosis; PE= pulmonary embolism.
F IGURE 2 Anticoagulant and antiplatelet agents utilized postdis-
charge. Among patients receivingwarfarin (n=186), 53 (28%) patients
were also prescribed LMWH for bridging anticoagulation at discharge
until the INR was therapeutic. These patients are not depicted sepa-
rately in this figure. DOAC = direct oral anticoagulant; LMWH = low
molecular weight heparin
including low-dose aspirin (n = 4), full-dose aspirin (n = 9), clopidogrel
(n= 1), and combination of aspirin and clopidogrel (n= 10).
Patientswhowere prescribed systemic anticoagulation had a lower
left ventricular ejection fraction, higher number of clinical and induced
VTs, and longerRF andprocedure time compared to patientswhowere
treated only with antiplatelets (Table 1).
After hospital discharge, no definite or possible thromboembolic
events (stroke, TIA, peripheral embolism) were documented within
the first 3 months postablation. Within the same period, 1 of the 190
(0.5%) patients who was treated with systemic anticoagulation post-
discharge experienced a major bleeding event 2 weeks after the pro-
cedure (thigh hematoma in the setting of supratherapeutic INR requir-
ing blood transfusion and correction of the coagulopathy). No bleed-
ing events were documented in the “antiplatelet only” group. Among
patients in the anticoagulation group with 3-month follow-up, there
were no instances of premature anticoagulation discontinuation.
4 DISCUSSION
4.1 Main findings
In this study, we report the safety and effectiveness of an anticoagula-
tion protocol for thromboembolic prophylaxis after RF catheter abla-
tion of infarct-related VT. Following standard intraprocedual anticoag-
ulation, patients with a large area of endocardial LV ablation received
a low-intensity and slowly escalating UFH infusion that was initiated
after adequate vascular access hemostasis was achieved, followed by
warfarin as the anticoagulant of choice for 3months. Patientswith lim-
ited endocardial ablation were treated only with antiplatelet agents
during follow-up. With this approach, we observed a very low risk of
postablation thromboembolic and bleeding events.
4.2 Pathogenesis of thromboembolism after VT
ablation
A variety of mechanisms may be implicated in the pathogenesis of
thromboembolism during or shortly after RF ablation:6 preformed
intracardiac thrombus mobilized by a catheter, de novo coagulum
formation on a catheter and at the sites of endocardial tissue damage,
heat-denatured albuminmicroparticle formation, and dislodgement of
aortic atheromatous material when a retrograde aortic approached is
used. Infarct-related VT ablation procedures are particularly relevant
in the study of thromboembolism pathogenesis and prophylaxis. First,
patients with a history of coronary artery disease and myocardial
infarction are more likely to have regional myocardial dysfunction
(including LV aneurysms) predisposing to blood stasis and thrombus
formation. These patients also frequently have significant aortic
atheromas, which can complicate LV access via a retrograde aortic
approach, as well as peripheral arterial disease, which can increase
the risk of access-related complications with postprocedure antico-
agulation. Finally, thrombogenicity may be increased with prolonged,
complex procedures and longer RF time, such as in scar-related VT
ablation.7
4.3 Current approaches for thromboembolic
prophylaxis postablation
Intraprocedural anticoagulation is universal in LV VT ablations, but
there is no established approach for thromboembolic prophylaxis
immediately after or in the first few weeks postablation and prac-
tices vary between centers. In the landmark Multicenter Thermocool
VT Ablation Trial, warfarin was used for 3 months if ablation was
performed over an area with >3 cm between ablation sites.4 The
subsequent EHRA/HRS Expert Consensus on Catheter Ablation of
Ventricular Arrhythmias also recommended a 6–12 week course of
warfarin after ablation over large endocardial areas (several square
centimeters).5 The Consensus Statement also recommended bridging
anticoagulation while therapeutic warfarin is being instituted. How-
ever, to date there are no comparative studies between different anti-
coagulation approaches. The study of periprocedural thromboembolic
risk factors and prophylaxis strategies remains challenging partly due
SIONTIS ET AL. 589
to the fact that thromboembolism is an infrequent complication of VT
ablation. No thromboembolic events were documented in either the
preapproval or in the postapproval Thermocool VT study.4,8 In two
other studies of VT ablation in structural heart disease, the reported
rates of thromboembolism were 0.8% and 0.5%,9,10 similar to the rate
of early postablation thromboembolism observed in our study. In an
earlier study of structural VT ablation utilizing an ablation catheter
with closed-loop irrigation, the rate of periprocedural cerebrovascular
eventswas higher (2.7%),11 whichmay be attributable to the increased
thrombogenicity of the closed-loop compared to the open irrigation
configuration for catheter tip cooling.12 The use of postprocedural
anticoagulation in these studies was not specified.
4.4 Asymptomatic cerebral embolism
Even though clinically overt thromboembolic events are infrequent
after LV ablation, asymptomatic cerebral embolismmay bemuchmore
common. This phenomenon has been well recognized in LA ablations
for AF13 andmay be associatedwith adverse neurocognitive effects,14
which highlights the importance of meticulous anticoagulation in abla-
tion procedures of the left-sided cardiac chambers. In a recent study
of 18 patients who underwent brain MRI within 1 week after endo-
cardial ablation for ventricular arrhythmias (predominantly premature
ventricular complexes), 58% of the patients were found to have a sub-
clinical embolic event after LV ablation. In comparison, no patients
undergoing exclusively RV ablation had embolic events.3 Similar to
the current study, most procedures were done via a retrograde aortic
approach. Patientswere treatedwith81mg/dayof aspirin if an embolic
event was found on MRI, but otherwise no standardized approach to
postprocedural anticoagulation was used. Whether routine postpro-
cedure bridging anticoagulation can prevent such embolic events is
unknown as the timing (intra- or postprocedural) and mechanism of
theseevents areunclear.Also, in that study, contact force-sensing abla-
tion catheters were used while in our cohort only noncontact force-
sensing catheters were used. AF ablation studies have demonstrated a
difference in the risk of silent cerebral embolismwith different types of
catheters.15 Whether such differences exist among the catheters that
are currently utilized in LV ablation procedures requires further study.
4.5 Bleeding risk
The benefits of anticoagulation should be balanced against the risk of
access and nonaccess site bleeding. The thrombogenic potential may
be highest in the early postablation period (<48 hours).16 However,
instituting early aggressive anticoagulation may expose the patient
to an increased access-related bleeding risk. Therefore, a low-dose,
slowly escalating, no-bolus regimen of UFH starting a few hours after
access hemostasis allows for the introduction of anticoagulation while
monitoring for bleeding complications. A benefit of using UFH is the
easy reversibility of its effect by discontinuing the infusion and by
administration of protamine in case of bleeding. On the other hand,
LMWH is an effective and convenient anticoagulant, but it has been
avoided early postprocedure (<48 hours) at our institution due to the
risk of access site bleeding from femoral arterial accesswith large bore
sheaths. In some patients with low bleeding risk who tolerated the
low-dose UFH infusion, LMWH was used as a bridge to therapeutic
warfarin in order to expedite discharge from the hospital. Similarly,
the rapid onset of action and limited reversal options of DOACs may
limit their use after VT ablation with arterial access. However, DOACs
may be a reasonable alternative for anticoagulation in patients with
low bleeding risk, especially if only venous access is used. An ongoing
study is currently investigating the use of apixaban after scar-related
VT ablation (NCT02666742).
4.6 Limitations
In this study, themajority of patients underwent extensive LV ablation,
thus the number of patients treated only with antiplatelet agents was
small. In addition, thromboembolic and bleeding events were infre-
quent, thus the comparative effects of therapeutic anticoagulation ver-
sus only antiplatelet therapy cannot be addressed adequately. Larger
sample sizes are required to achieve sufficient statistical power. We
also did not have a control group in whom a different thromboembolic
prophylaxis protocol was used.
5 CONCLUSION
After infarct-related VT ablation involving extended areas of the LV
endocardium, a low-dose, slowly escalating regimen of UFH for bridg-
ing anticoagulation, followed by 3 months of therapeutic anticoagu-
lation is associated with low thromboembolic and bleeding risks. In
patients without extensive endocardial ablation, antiplatelet therapy
alone appears reasonable. The comparative effectiveness and safety of
different thromboembolic prophylaxis approaches, as well as the role
of DOACs after VT ablation require further investigation.
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